Brand-name Wegovy and Zepbound are sometimes covered for patients with documented obesity (BMI 30+) or BMI 27+ with a comorbid condition
For CPG brands and retailers, the opportunity is concentrated in formats that align with these consumption patterns: GLP-1 friendly frozen meals High-protein prepared foods Fiber-rich snacks and beverages Portion-controlled meal formats These categories match how GLP-1 users actually eat: smaller portions, higher nutritional density, and convenient meals
Our focus is on medications with stronger long-term efficacy and safety profiles, supported by genetic personalization through the Precision Peptide Genetic Test to optimize your individual response
A limitation of the current review is that it focused on indirect comparisons of 24-h continuous monitoring studies that differed in terms of study population (e.g., obese or not-obese, ambulatory or not-ambulatory), study treatment (e.g., continuous intravenous infusion, or oral administration) and timing of assessment after variable duration of study treatment
Franco et al., 2007b
Common : Nausea (up to 44%), vomiting, diarrhea, constipation Less common : Fatigue, dyspepsia, bloating, dizziness Rare : Cholelithiasis, acute pancreatitis Serious : Risk of thyroid tumors (animal data), kidney impairment due to dehydration Proper storage is critical to maintaining the products efficacy